Literature DB >> 15986186

A proof-of-concept study using [11C]flumazenil PET to demonstrate that pagoclone is a partial agonist.

A Lingford-Hughes, S J Wilson, A Feeney, P G Grasby, D J Nutt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15986186     DOI： 10.1007/s00213-005-0060-1

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN： 0033-3158            Impact factor:   4.530


× No keyword cloud information.
  8 in total

1.  Anti-Tremor Action of Subtype Selective Positive Allosteric Modulators of GABAA Receptors in a Rat Model of Essential Tremors.

Authors:  Dipak V Amrutkar; Tino Dyhring; Thomas A Jacobsen; Janus S Larsen; Karin Sandager-Nielsen
Journal:  Cerebellum       Date:  2020-04       Impact factor: 3.847

2.  Pharmacology in translation: the preclinical and early clinical profile of the novel α2/3 functionally selective GABAA receptor positive allosteric modulator PF-06372865.

Authors:  Sarah A Nickolls; Rachel Gurrell; Guido van Amerongen; Juha Kammonen; Lishuang Cao; Adam R Brown; Clara Stead; Andy Mead; Christine Watson; Cathleen Hsu; Robert M Owen; Andy Pike; Rebecca L Fish; Laigao Chen; Ruolun Qiu; Evan D Morris; Gang Feng; Mark Whitlock; Donal Gorman; Joop van Gerven; David S Reynolds; Pinky Dua; Richard P Butt
Journal:  Br J Pharmacol       Date:  2018-01-18       Impact factor: 8.739

3.  Evidence That Sedative Effects of Benzodiazepines Involve Unexpected GABAA Receptor Subtypes: Quantitative Observation Studies in Rhesus Monkeys.

Authors:  Angela N Duke; Zhiqiang Meng; Donna M Platt; John R Atack; Gerard R Dawson; David S Reynolds; V V N Phani Babu Tiruveedhula; Guanguan Li; Michael Rajesh Stephen; Werner Sieghart; James M Cook; James K Rowlett
Journal:  J Pharmacol Exp Ther       Date:  2018-05-02       Impact factor: 4.030

4.  The central nervous system effects of the partial GABA-Aα2,3 -selective receptor modulator AZD7325 in comparison with lorazepam in healthy males.

Authors:  Xia Chen; Gabriël Jacobs; Marieke de Kam; Judith Jaeger; Jaakko Lappalainen; Paul Maruff; Mark A Smith; Alan J Cross; Adam Cohen; Joop van Gerven
Journal:  Br J Clin Pharmacol       Date:  2014-12       Impact factor: 4.335

5.  Reducing abuse liability of GABAA/benzodiazepine ligands via selective partial agonist efficacy at alpha1 and alpha2/3 subtypes.

Authors:  Nancy A Ator; John R Atack; Richard J Hargreaves; H Donald Burns; Gerard R Dawson
Journal:  J Pharmacol Exp Ther       Date:  2009-09-29       Impact factor: 4.030

6.  A Comparison of the α2/3/5 Selective Positive Allosteric Modulators L-838,417 and TPA023 in Preclinical Models of Inflammatory and Neuropathic Pain.

Authors:  Sarah Nickolls; Hannah Mace; Rebecca Fish; Michelle Edye; Rachel Gurrell; Magnus Ivarsson; Tom Pitcher; Sachi Tanimoto-Mori; Denise Richardson; Catherine Sweatman; Janet Nicholson; Cameron Ward; John Jinks; Christine Bell; Kimberly Young; Huw Rees; Andrew Moss; Ross Kinloch; Gordon McMurray
Journal:  Adv Pharmacol Sci       Date:  2011-11-28

7.  GABAA receptor occupancy by subtype selective GABAAα2,3 modulators: PET studies in humans.

Authors:  Aurelija Jucaite; Zsolt Cselényi; Jaakko Lappalainen; Dennis J McCarthy; Chi-Ming Lee; Svante Nyberg; Katarina Varnäs; Per Stenkrona; Christer Halldin; Alan Cross; Lars Farde
Journal:  Psychopharmacology (Berl)       Date:  2016-12-24       Impact factor: 4.530

8.  Preliminary effects of pagoclone, a partial GABA(A) agonist, on neuropsychological performance.

Authors:  Angela F Caveney; Bruno Giordani; George M Haig
Journal:  Neuropsychiatr Dis Treat       Date:  2008-02       Impact factor: 2.570
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.